GE Research and Collaborators Awarded DARPA Project to Improve Speed of Nucleic Acid-based Vaccine Manufacture and Distribution

• Mobile platform intended to produce -1,000s of ready-to-use doses at the site of need in under 3 days
• Project leverages GE’s expertise regarding synthetic method for producing industrial amounts of DNA
• GE’s DNA-based approach could be compatible with new, recently approved RNA-based COVID-19 vaccines

Aiming to enable vaccine production on-demand, anywhere in the world in just days, GE Research and a multi-disciplinary team that includes the Broad Institute, DNA Script, MEDInstill,  Molecular Assemblies, and the University of Washington, have been awarded a five-year, up to $41 million project through a new program from the Defense Advanced Research Projects Agency (DARPA) called NOW (Nucleic Acids On-Demand Worldwide). Such a rapidly scalable and deployable production process could dramatically increase the speed at which new vaccines, such as the recently approved COVID-19 vaccines, could be deployed to people in need.

DARPA’s NOW program, managed by Dr. Amy Jenkins in the Biological Technologies Office, was created to develop a rapid, mobile medical manufacturing platform for producing, formulating, and packaging DNA and/or RNA-based vaccines and therapeutics for use in stabilization and humanitarian operations and to better prepare deployed, field-forward forces against bio-threat attacks and emerging infectious disease. Developing this type of platform would enable the deployment of vaccines and therapeutics in just days vs. weeks.

GE’s project, called RUN FAST (Rapid Universal Nucleic Acids using Fieldable Automated Synthesis Technology), will leverage the expertise of the GE Research team, led by John R. Nelson, Ph.D., building automated systems in the biological production of medicines and therapies with a novel synthetic method for making DNA and RNA to assemble a complete mobile medical manufacturing platform.  Dr. Nelson, the principal investigator of the project, says this type of platform could be a game-changer, stating, “We think the world really needs this kind of advance to be prepared for unexpected challenges like what we have seen recently with COVID-19. Having the ability to produce small batches of ready-to-use vaccines in under 3 days at the site of need would enable widespread deployment of doses at an unprecedented speed.”

The GE team, comprised of Dr. Nelson and his colleagues, Weston Griffin, Ph.D., Erik Kvam, Ph.D., and Brian Davis, Ph.D., represents a highly multi-disciplinary group with deep expertise in chemistry, molecular biology, cell biology, fluidic handling, engineering, automation, and quality control to simplify the production of DNA therapies. Together with their project partners, they bring all of the elements required to design this mobile manufacturing platform.

Until just recently, all the steps required to produce a DNA or RNA- based vaccine were manual, and significantly, required the use of bacterial cultures for bio-production of the DNA used. This use of bacterial cells then necessitates the use of multiple purification steps to eliminate impurities. DARPA recognized the unique and broad capabilities of this team not only to incorporate synthetic DNA production, but to automate and integrate all of the steps into a streamlined workflow to create this portable production system.

The novel synthetic method to produce industrial amounts of DNA, Dr. Nelson says, will be key towards enabling the new production system, stating, “Our team has experience and expertise using enzymes to make DNA synthetically instead of purifying it from living cells. This eliminates the requirement for bacterial cultures and the purification steps that entails. We believe that this reaction can be scaled easily in size and because it doesn’t use living cells that need to be fed and cared for and cleaned up after, can be automated.”

Dr. Nelson and the GE Research team is in the final stages of a project with the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA) to develop a faster method for making doses of DNA-based vaccines.  Similar to the new DARPA project, the team’s research and technology is focused on the speed of amplifying or scaling the manufacture of a given vaccine.  The new project with DARPA represents a significant opportunity to accelerate needed advancement to ready this new mobile vaccine production platform.

About GE Research

GE Research is GE’s innovation powerhouse where research meets reality. We are a world-class team of scientific, engineering and marketing minds working at the intersection of physics and markets, physical and digital technologies, and across a broad set of industries to deliver world-changing innovations and capabilities for our customers. To learn more, visit our website at https://www.ge.com/research/.